Fremanezumab Autoinjector Device Approved by FDA

Anti-CGRP treatment for migraine available as autoinjector and prefilled syringe

The new autoinjector device for fremanezumab (AJOVY®) has received FDA approval, providing adult patients with migraine another option for administering the anti-CGRP treatment. Previously, this medication was only available as a prefilled syringe. This change allows patients flexibility in how they administer this treatment. 

The autoinjector device is expected to be available to patients in the coming months. Hypersensitivity reactions were reported in clinical trials and include rash, pruritus, drug hypersensitivity and urticaria. Most reactions were reported from within hours to one month after administration and were mild to moderate. Some reactions led to discontinuation or required corticosteroid treatment. The most common adverse reaction is injection site reactions. 

Learn more about the fremanezumab autoinjector device here.

Read the latest in the field of headache medicine by visiting the American Headache Society’s News Library.